| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 4 | +75.00% | -5.68% | +0.87% | -6.55% | -8.95% | — |
| 14d | 4 | +75.00% | -4.58% | +0.54% | -5.12% | -4.75% | — |
| 30d | 4 | +75.00% | -0.17% | +1.53% | -1.70% | -5.00% | — |
| 60d | 4 | +100.00% | -29.89% | +3.80% | -33.70% | -34.08% | — |
| 90d | 4 | +100.00% | -45.06% | +5.68% | -50.75% | -49.86% | — |
| 180d | 4 | +100.00% | -76.38% | +5.68% | -82.06% | -79.99% | — |
| 1y | 4 | +100.00% | -82.64% | +11.83% | -94.47% | -92.91% | — |
| 2y | 4(2 pending) | +100.00% | -95.90% | +33.30% | -129.20% | -129.20% | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| DFTX DEFINIUM THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 2,867 | $45.03 | $129.1K | 174,633 | Jun 25, 2026 | Jun 26, 2026 ↗ | View → |
| DFTX DEFINIUM THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 62,500 | — | — | 177,500 | Jun 22, 2026 | Jun 22, 2026 ↗ | View → |
| DFTX DEFINIUM THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 115,000 | — | — | 115,000 | Feb 3, 2026 | Feb 5, 2026 ↗ | View → |
| BTAI BIOXCEL THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 6,272 | $0.55 | $3.4K | 19,011 | Oct 3, 2024 | Oct 3, 2024 ↗ | View → |
| BTAI BIOXCEL THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 21,250 | — | — | 25,283 | Sep 17, 2024 | Oct 3, 2024 ↗ | View → |
| BTAI BIOXCEL THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 215 | $0.69 | $149 | 4,033 | Sep 16, 2024 | Sep 17, 2024 ↗ | View → |
| BTAI BIOXCEL THERAPEUTICS, INC. | SALE Chief Commercial Officer | 750 | — | — | 7,500 | Sep 15, 2024 | Sep 17, 2024 ↗ | View → |
| BTAI BIOXCEL THERAPEUTICS, INC. | PURCHASE Chief Commercial Officer | 750 | — | — | 4,248 | Sep 15, 2024 | Sep 17, 2024 ↗ | View → |
| BTAI BIOXCEL THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 1,875 | — | — | 1,875 | Jul 22, 2024 | Apr 1, 2025 ↗ | View → |
| BTAI BIOXCEL THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 244 | $1.26 | $308 | 3,498 | Jun 17, 2024 | Jun 18, 2024 ↗ | View → |
| BTAI BIOXCEL THERAPEUTICS, INC. | PURCHASE Chief Commercial Officer | 750 | — | — | 8,250 | Jun 15, 2024 | Jun 18, 2024 ↗ | View → |
| BTAI BIOXCEL THERAPEUTICS, INC. | PURCHASE Chief Commercial Officer | 750 | — | — | 3,742 | Jun 15, 2024 | Jun 18, 2024 ↗ | View → |
| BTAI BIOXCEL THERAPEUTICS, INC. | SALE Chief Commercial Officer | 750 | — | — | 8,250 | Jun 15, 2024 | Sep 17, 2024 ↗ | View → |
| BTAI BIOXCEL THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 1,008 | $2.64 | $2.7K | 2,992 | Apr 4, 2024 | Apr 8, 2024 ↗ | View → |
| BTAI BIOXCEL THERAPEUTICS, INC. | PURCHASE CHIEF COMMERCIAL OFFICER | 3,000 | — | — | 9,000 | Mar 15, 2024 | Apr 8, 2024 ↗ | View → |
| BTAI BIOXCEL THERAPEUTICS, INC. | PURCHASE CHIEF COMMERCIAL OFFICER | 3,000 | — | — | 3,000 | Mar 15, 2024 | Apr 8, 2024 ↗ | View → |
| BTAI BIOXCEL THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 12,000 | — | — | 12,000 | Mar 15, 2023 | Mar 16, 2023 ↗ | View → |
| BTAI BIOXCEL THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 36,000 | — | — | 36,000 | Mar 15, 2023 | Mar 16, 2023 ↗ | View → |
| BTAI BIOXCEL THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 85,000 | — | — | 85,000 | Jan 17, 2022 | Jan 19, 2022 ↗ | View → |
| VYNE YARROW BIOSCIENCE, INC. | SALE Chief Commercial Officer | 5,151 | $3.51 | $18.1K | 109,246 | Jun 30, 2021 | Jul 2, 2021 ↗ | View → |
| VYNE YARROW BIOSCIENCE, INC. | SALE Chief Commercial Officer | 2,573 | $6.84 | $17.6K | 114,397 | Mar 31, 2021 | Apr 2, 2021 ↗ | View → |
| VYNE YARROW BIOSCIENCE, INC. | PURCHASEGRANT Stock grant | 27,675 | — | — | 116,970 | Feb 22, 2021 | Feb 24, 2021 ↗ | View → |
| VYNE YARROW BIOSCIENCE, INC. | PURCHASEGRANT Stock grant | 64,575 | — | — | 64,575 | Feb 22, 2021 | Feb 24, 2021 ↗ | View → |
| VYNE YARROW BIOSCIENCE, INC. | SALE Chief Commercial Officer | 1,541 | $1.58 | $2.4K | 357,181 | Dec 31, 2020 | Jan 5, 2021 ↗ | View → |
| VYNE YARROW BIOSCIENCE, INC. | PURCHASEGRANT Stock grant | 7,838 | $1.45 | $11.3K | 358,722 | Nov 30, 2020 | Dec 2, 2020 ↗ | View → |
| VYNE YARROW BIOSCIENCE, INC. | SALE Chief Commercial Officer | 1,541 | $1.66 | $2.6K | 350,884 | Sep 30, 2020 | Oct 2, 2020 ↗ | View → |